Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance.
Krook MA, Reeser JW, Ernst G, Barker H, Wilberding M, Li G, Chen HZ, Roychowdhury S. · 2021
Read Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. by Krook MA, Reeser JW, Ernst G, Barker H, Wilberding M, Li G, Chen HZ, Roychowdhury S. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7921129.txt.
Introduction
Krook and co-authors present a review of fibroblast growth factor receptors in cancer. These receptors are switched on wrongly in 5–10% of all human cancers. Faults include single-letter changes, gene fusions, and extra gene copies. In bladder and bile duct cancers, the share rises to 10–30%. The review maps this landscape and the fight against it.
The authors first cover the hard task of testing for these faults in tissue and blood. They then survey the drugs built to block the receptors. Two drugs, erdafitinib and pemigatinib, already hold approval for defined cancer types. Most patients who first respond later grow resistant. The review sets out how that resistance arises, inside the tumour and beyond it. It closes with the next wave of blockers and fresh treatment plans.
Catalog record
| CREATOR | Krook MA, Reeser JW, Ernst G, Barker H, Wilberding M, Li G, Chen HZ, Roychowdhury S. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 79 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance By Melanie A Krook, Julie W Reeser, Gabrielle Ernst, Hannah Barker, Max Wilberding, Gary Li, Hui-Zi Chen, Sameek Roychowdhury Published in: British Journal of Cancer DOI: 10.1038/s41416-020-01157-0 ABSTRACT Abstract Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-nucleotide variants, gene fusions and copy number amplifications in 5–10% of all human cancers, although this frequency increases to 10–30% in urothelial carcinoma and intrahepatic cholangiocarcinoma. We begin this review by highlighting the diversity of FGFR genomic alterations identified in human cancers and the current challenges associated with the development of clinical-grade molecular diagnostic tests to accurately detect these alterations in the tissue and blood of patients. The past decade has seen significant advancements in the development of FGFR-targeted therapies, which include selective, non-selective and covalent small-molecule inhibitors, as well as monoclonal antibodies against the receptors. We describe the expanding landscape of anti-FGFR therapies that are being assessed in early phase and randomised controlled clinical trials, such as erdafitinib and pemigatinib, which are approved by the Food and Drug Administration for the treatment of FGFR3-mutated urothelial carcinoma and FGFR2-fusion cholangiocarcinoma, respectively. However, despite initial sensitivity to FGFR inhibition, acquired drug resistance leading to cancer progression develops in most patients. This phenomenon underscores the need to clearly delineate tumour-intrinsic and tumour-extrinsic mechanisms of resistance to facilitate the development of second-generation FGFR inhibitors and novel treatment strategies beyond progression on targeted therapy. Subject terms: Cancer, Cancer BACKGROUND The fibroblast growth factor receptor (FGFR) family of receptor tyrosine kinases consists of four transmembrane receptors, FGFR1–4.1 Each receptor contains three extracellular immunoglobulin (Ig)-like binding domains, followed by a transmembrane domain and an intracellular domain constituting a two-part tyrosine kinase.1 Twenty-two known fibroblast growth factor (FGF) ligands exist, yet only 18 of these ligands2 interact with, and induce the dimerisation of, these four receptors to stimulate their kinase activity and activate downstream signalling pathways through the intracellular domain. These pathways include the extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) pathway, which promotes cell survival, proliferation, development, angiogenesis and differentiation.3–6 Consequently, aberrations in FGFR1–4—including single-nucleotide variants (SNVs), gene rearrangements or fusions, and copy number amplifications (CNAs)—are detected in 5–10% of all human cancers, although some types, such as urothelial cancer and intrahepatic cholangiocarcinoma (iCCA), display an increased (10–30%) frequency of FGFR aberrations (Fig. 1).3,7–9 Given the diversity of FGFR alterations, in particular with fusions as drivers, in solid tumour and haematological cancers, there is an emerging need for clinical-grade molecular diagnostic tests to accurately detect these aberrations in both tumour tissues and blood samples. The repertoire of FGFR-targeted therapies has expanded to include non-selective tyrosine kinase inhibitors (TKIs), selective TKIs, covalent TKIs, monoclonal antibodies and antibody–drug conjugates (ADCs), and FGF ligand traps. Two anti-FGFR therapies have recently been approved by the Food and Drug Administration (FDA), including erdafitinib for FGFR3-altered urothelial cancer and pemigatinib for FGFR2-fusion cholangiocarcinoma.10,11 While the majority of patients are initially sensitive to FGFR-targeted therapies, many develop acquired resistance ultimately resulting in disease progression and discontinuation of therapy. Secondary genomic alterations responsible for TKI resistance are becoming more defined, such as gatekeeper mutations in the FGFR kinase domain. Additional mechanistic studies are clearly needed to fully elucidate the complexities of acquired resistance, including undefined molecular contributions from the tumour stroma and immune system. Only a full understanding of how different cell types and their interplay behave in various cellular contexts that mediate resistance will lead to the development of second and subsequent generation of TKIs and combinatorial therapies. In this review, we will catalogue the diversity of FGFR alterations in human cancers, discuss the challenges associated with molecular diagnostic tests being developed to detect these alterations for clinical actionability, review the diverse portfolio of first-generation anti-FGFR therapies and summarise current known mechanisms of acquired resistance. [Figure: Cancer types that harbour alterations in FGFR.FGFR alterations, including single-nucleotide variants (SNVs), fusions and copy number amplifications (CNAs) have been frequently detected in multiple types of human cancer at varying percentages.] FGFR ALTERATIONS IN CANCER Advances in sequencing technologies in recent years have led to the discovery of diverse FGFR genomic alterations that have been shown to occur at varying frequencies across numerous tumour types. Helsten et al.3 reported that of the 7.1% of FGFR1–4-altered cancers in their cohort of 4853 tumours, 66% of the aberrations were due to CNAs, while 26% were SNVs, and 8% were gene rearrangements or fusions. In a separate retrospective analysis of 274,694 patient tumour samples, genomic alterations in FGFR1–3 (FGFR4 was not assessed) were detected by next-generation sequencing in 2.3% of patient specimens, of which 64.8% were SNVs and 35.9% were rearrangements.12 In both studies, almost all tumour types were found to have FGFR alterations, but those with the highest alteration frequency included urothelial cancer, cholangiocarcinoma, endometrial cancer, squamous lung cancers, breast cancer and cervical cancer.3,12 In this section, we catalogue the diversity of FGFR SNVs, gene fusions and CNAs. Single-nucleotide variants Somatic activating FGFR1–4 SNVs can cause the receptor to be constitutively active by conferring increased dimerisation, increased kinase activity or enhanced affinity for FGF ligands.1 Unlike other kinases, such as epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR), in which activating SNVs tend to occur exclusively within the kinase domain, SNVs in FGFR1–4 have been reported in the extracellular domain, the transmembrane domain and the intracellular kinase domain.12,13 A recent large retrospective analysis of next-generation sequencing (NGS) data from >250,000 patient samples identified over 250 unique SNVs distributed throughout the different domains of FGFR1–3, highlighting the vast diversity of FGFR SNVs seen across cancer types.12 FGFR1 SNVs are rare and have been reported in fewer cases of cancer in comparison with FGFR2 and FGFR3. The two most common activating mutations in FGFR1 are N546K and K656E, both of which reside in the kinase domain and result in increased kinase activation and transformation in vitro.3,14–16 Although the functional consequence is unknown, the S125L mutation has been reported in both breast and gallbladder cancer.17,18 The majority of SNVs in FGFR have been reported to occur in FGFR2 and are found at high frequencies in endometrial cancer (12%), non-small cell lung cancer (4%) and gastric cancer (4%).1,19,20 Interestingly, these somatic-activating FGFR2 mutations predominantly occur in the transmembrane (Y375C, C382Y/R) and extracellular domains (S252W, W290C, P253R) rather than the kinase domain (N549H/K, K659E).3 Extensive in vitro and in vivo analyses of these mutations have revealed that their oncogenic potential is due to increased receptor–ligand binding affinity and receptor dimerisation. Furthermore, studies have revealed that these mutations are highly sensitive to FGFR inhibition. Activating FGFR3 mutations have been identified in 10–60% of urothelial carcinomas, predominately in low-grade tumours.21 The most frequent FGFR3 SNVs were R248C and S249C occurring in the extracellular domain, as well as G370C and Y373C occurring in the transmembrane domain.1 The resulting cysteine residues from these mutations lead to ligand-independent dimerisation of the receptor.22 In addition, FGFR3 mutations have been reported to occur in 5% of cervical carcinomas.23 FGFR4 SNVs are notable for their prevalence in rhabdomyosarcoma, occurring in 7–8% of cases.24 Specifically, V550E, a gatekeeper mutation, and N535K both contribute to autophosphorylation and constitutive activation of the kinase.25 In a transcriptome screen of